Hemophilia – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Hemophilia Emerging Therapy and TPP Insights

Thelansis’s “Hemophilia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Hemophilia Overview

Hemophilia is a rare inherited bleeding disorder caused by a deficiency or dysfunction of clotting factors, most commonly factor VIII (hemophilia A) or factor IX (hemophilia B). The condition is X‑linked, primarily affecting males, and is characterized by prolonged bleeding after injury, frequent bruising, and spontaneous hemorrhages into joints and muscles that can lead to chronic pain and disability. Severity depends on the level of clotting factor activity, with severe cases presenting early in life and mild forms sometimes detected only after surgery or trauma. Diagnosis is confirmed through coagulation studies and factor assays. Management involves replacement therapy with clotting factor concentrates, either on‑demand or prophylactically, and newer approaches such as extended‑half‑life products and gene therapy are transforming long‑term care. Despite advances, hemophilia remains associated with significant treatment burden and risk of complications, underscoring the importance of early diagnosis, individualized therapy, and comprehensive multidisciplinary care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Hemophilia – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025